Cornea/External Disease News

Reproxalap for the treatment of allergic conjunctivitis achieved the primary and secondary endpoints in the phase 3 INVIGORATE-2 clinical trial, according to a press release from Aldeyra Therapeutics.

A water-free cyclosporine solution showed efficacy in improving the signs and symptoms of dry eye disease in a randomized clinical trial.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, David Eveleth, PhD, CEO of Trefoil Therapeutics, speaks about the results of TTHX1114 following Descemet stripping only and cataract surgery.

KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Susan Benton and Darrell E. White, MD, provide an overview of the Preservative Freedom Coalition, which was recently launched by Thea Pharma.

The FDA approved Vevye, a 0.1% cyclosporine ophthalmic solution, for the treatment of signs and symptoms of dry eye disease, according to a press release from Novaliq.

In the cover story of this issue of Healio/Ocular Surgery News, we explore the challenges of treating ocular surface infections like contact lens-related corneal ulcers.

Antimicrobial peptides are touted as potential new antibiotics to help treat ocular surface infections. Yet, we have been using these since at least the 1970s.

The eye is well adept at protecting itself against pathogens. There are antimicrobial proteins in tears, and the intact epithelium on the surface of the eye shields it efficiently from external assaults.

Historically, pterygium excision techniques were complicated and inconsistent, undermining many surgeons’ confidence and often leading to delays in surgery until the pterygium had progressed into the visual axis.

Ocular surface infections include infectious conjunctivitis and infectious keratitis.